Active, not recruitingPhase 2NCT07549646

24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs

Studying Cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Children's Hospital of Philadelphia
Intervention
Trametinib(drug)
Enrollment
45 target
Eligibility
30 years · All sexes
Timeline
2025 – 2030

Study locations (1)

Collaborators

Novartis · CaNVAS (Consortium of Investigators of Vascular Anomalies) · Texas Children's · Arkansas Children's Hospital Research Institute · Nationwide Children's Hospital · Nemours Children's Health · Boston Children's Hospital · NYU Langone Health · Children's Healthcare of Atlanta · Oregon Health and Science University · Children's Hospital Colorado · Riley Children's Health · Children's Hospital of Los Angeles (CHLA) · Seattle Children's Hospital · Children's Hospital of Orange County (CHOC) · Children's Wisconsin - Milwaukee · University of North Carolina · Children's Hospital Medical Center, Cincinnati · University of California, San Francisco · Columbia University · Children's Hospital of Pittsburg · Dell Children's Medical Center of Central Texas · Vanderbilt University Medical Center · Helen DeVos Children's Hospital · Washington University School of Medicine · Lucile Packard Children's Hospital Stanford

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07549646 on ClinicalTrials.gov

Other trials for Cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome

Additional recruiting or active studies for the same condition.

See all trials for Cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome →

← Back to all trials